[ad_1] CNN — A congressional investigation found that the US Food and Drug Administration’s “atypical collaboration” to approve a high-priced Alzheimer’s drug was “rife with irregularities.” The report, released Thursday, was the result of an 18-month investigation by two House committees. It is sharply critical of Biogen, maker of the …
Read More »
[ad_1] A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Check out the companies making the biggest moves midday: Apple — Apple shares fell 2% following a report that iPhone production could take a big hit due to unrest at a Foxconn factory in China, amid protests in China …
Read More »
[ad_1] Eli Lilly (LLY) CEO David Ricks on Tuesday expressed optimism around the drugmaker’s innovation pipeline Tuesday, a stance we share despite the Club holding’s cluttered quarterly report issued earlier in the day . “The underlying fundamentals of the business are really strong,” Ricks said in a CNBC interview with …
Read More »
[ad_1] Revlon signage is seen on display in a Boots store in London, Britain, June 16, 2022. Hannah McKay | Reuters Check out the companies making headlines in midday trading. Digital World Acquisition — The company planning to take Donald Trump’s media company Truth Social public surged 14.6%, continuing its …
Read More »
[ad_1] Biogen ‘s new Alzheimer’s treatment could lead to even stronger gains for the biotech company going forward, according to Stifel. Analyst Paul Matteis upgraded shares of the biotech company to buy from hold, saying that upcoming data for Alzheimer treatments from competitors Roche and Eli Lilly could show that …
Read More »
[ad_1] CNBC’s Jim Cramer on Tuesday gave his take on the winning and losing stocks in the S&P 500 during the third quarter. “This is a harsh market with harsh criteria. Constellation Energy and Enphase can meet those criteria, but everything else in the winner’s circle seems capricious, and the …
Read More »
[ad_1] Biopharma companies are having more clinical success treating Alzheimer’s disease and obesity and are taking new approaches in oncology, and that’s creating more mega-blockbuster drugs, according to Bank of America. Analyst Geoff Meacham has identified 20 drugs that have the potential to generate $10 billion or more in annual …
Read More »
[ad_1] We don’t own Eli Lilly exclusively for its potential Alzheimer’s treatment. However, we still find Biogen’s topline data to be very encouraging for Lilly. [ad_2] Source link
Read More »
[ad_1] A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen will pay $900 million to settle a lawsuit that alleged the company gave doctors kickbacks to encourage them prescribe its drugs, the Justice Department announced on Monday. A former Biogen employee turned whistleblower, Michael Bawduniak, sued the pharmaceutical …
Read More »